^
CANCER:
Genito-urinary Cancer
No biomarker
RCC
pembrolizumab + lenvatinib
Sensitive
:
B
Merck (MSD) Press Release - 1d
No biomarker
Prostate Cancer
enzalutamide
Sensitive
:
A1
Astellas Press Release - 3d
No biomarker
Prostate Cancer
apalutamide
Sensitive
:
A1
J Clin Oncol - 1wk
No biomarker
Urothelial Cancer
nivolumab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 1wk
No biomarker
Urothelial Cancer
pembrolizumab
Sensitive
:
A1
NICE - 1wk
No biomarker
RCC
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 1wk
NF2 mutation
Kidney Medullary Carcinoma
bevacizumab + erlotinib
Sensitive
:
C4
Cancers (Basel) - 1wk
RB1 mutation + TP53 mutation
Urothelial Cancer
atezolizumab
Sensitive
:
C3
BMC Cancer - 2wk
RAD52 underexpression
Bladder Cancer
cisplatin
Resistant
:
C3
Int J Mol Sci - 2wk
No biomarker
Urothelial Cancer
sacituzumab govitecan-hziy
Sensitive
:
A1
FDA - 3wk
No biomarker
Urothelial Cancer
toripalimab
Sensitive
:
A1
GlobeNewswire - 3wk
NEIL3 deletion
Prostate Cancer
enzalutamide
Resistant
:
D
Int J Mol Sci - 3wk
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
avelumab
Sensitive
:
A1
PD-L1 expression
RCC
avelumab + axitinib
Sensitive
:
A1
No biomarker
Prostate Cancer
histrelin acetate
Sensitive
:
A1
No biomarker
Prostate Cancer
cabazitaxel
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
No biomarker
RCC
avelumab + axitinib
Sensitive
:
A1
No biomarker
RCC
Mvasi (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
RCC
Zirabev (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Prostate Cancer
relugolix
Sensitive
:
A1
No biomarker
Germ Cell Tumors
dactinomycin
Sensitive
:
A1
No biomarker
Testicular Cancer
etoposide IV
Sensitive
:
A1
No biomarker
Testicular Cancer
cisplatin
Sensitive
:
A1
No biomarker
Testicular Cancer
ifosfamide
Sensitive
:
A1
No biomarker
RCC
sorafenib
Sensitive
:
A1
No biomarker
RCC
tivozanib
Sensitive
:
A1
No biomarker
Urothelial Cancer
mitomycin urothelial gel
Sensitive
:
A1
No biomarker
RCC
temsirolimus
Sensitive
:
A1
No biomarker
RCC
sunitinib
Sensitive
:
A1
No biomarker
RCC
everolimus + lenvatinib
Sensitive
:
A1
No biomarker
Prostate Cancer
docetaxel + prednisone
Sensitive
:
A1
No biomarker
Prostate Cancer
abiraterone acetate
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our